1. Allergan plans to cut more than 1,000 jobs, as it braces itself for competition from a generic version of its blockbuster dry-eye treatment Restasis this year. (Bloomberg)
2. Pharmaceutical distributor McKesson Corporation acquired pharmacy services provider RxCrossroads from CVS Health. The purchase price was $735 million. (Drug Store News)
3. Pfizer will pay Sangamo Therapeutics $12 million upfront and $150 million in milestones to collaborate on the development of a gene therapy to treat ALS. (Endpoints News)
4. Novartis’ Promacta received Breakthrough Therapy Designation for first-line treatment of severe aplastic anemia, a rare blood disorder. Promacta first received FDA approval in 2008, when it was marketed by GlaxoSmithKline. (Reuters)
5. The Philippines fined Sanofi $2,000 and suspended the drugmaker’s certificate of product registration for dengue vaccine Dengvaxia. The certificate suspension prevents the drugmaker from selling, distributing, and marketing the vaccine in the country. (Reuters)
